Boston Scientific (BSX): Growth Reset, Still a Buy

Thesis

Boston Scientific(BSX) looks like a high-quality medtech compounder that has hit a real but manageable speed bump. The core case rests on three facts. First, the business is still growing at a pace most large-cap device peers would envy, with Q1 2026 net sales of $5.203B, up 11.6% reported and 9.4% organic. Second, the portfolio remains tilted toward attractive categories, especially Electrophysiology, WATCHMAN, Interventional Oncology, and Neuromodulation, which posted Q1 organic growth of 21.7%, 18.8%, 15.2%, and 15%, respectively. Third, the valuation has compressed sharply, with shares at $50.34 on May 27, 2026 against a consensus target of $83.47, a trailing P/E of 24.1, a forward P/E of 17.1, and a PEG ratio of 0.69.

The catch is execution, not franchise quality. Management cut full-year 2026 guidance on April 22, 2026 to 6.5% to 8.0% organic growth and $3.34 to $3.41 in adjusted EPS after softer trends in Electrophysiology, WATCHMAN, and Urology. That matters because BSX has earned its premium through consistent delivery. Still, the underlying numbers do not read like a broken growth story. Q1 adjusted EPS was $0.80 versus $0.79 consensus, the company has beaten EPS estimates in 7 straight reported quarters, free cash flow reached $3.66B in 2025, and gross debt leverage was 1.8x at March 31, 2026. For a balanced, moderate-risk investor with a medium-term horizon, BSX screens as a Buy: not because the quarter was clean, but because the market seems to be pricing a much deeper impairment than the operating data supports.

Company Overview

Boston Scientific(BSX) is a global medical device company headquartered in Marlborough, Massachusetts, with 59,000 employees and operations across interventional medical specialties worldwide. The company develops and markets minimally invasive devices used in cardiovascular care, electrophysiology, structural heart, endoscopy, urology, pelvic health, neuromodulation, and oncology. It trades on the NYSE and had a market capitalization of about $85.7B in the supplied valuation snapshot.

The business is organized into two reporting segments: Cardiovascular and MedSurg. In 2025, Cardiovascular generated $13.266B, or 66.0% of total revenue, while MedSurg generated $6.829B, or 34.0%. That mix has shifted toward Cardiovascular over time. In 2023, Cardiovascular was 61.9% of revenue; by 2025 it was 66.0%. That matters because the faster-growing franchises currently sit disproportionately in the Cardiovascular portfolio.

BSX’s model is procedure-driven. Revenue depends on hospital and physician use of devices in recurring clinical workflows rather than on one-off capital equipment cycles. That gives the company a steadier demand base than many health care businesses, but it also ties growth to hospital capacity, physician adoption, reimbursement, and clinical evidence. Q1 2026 showed both sides of that equation. Electrophysiology and Interventional Oncology remained strong, while WATCHMAN volumes in the U.S. softened as hospital procedure prioritization and reimbursement dynamics weighed on stand-alone cases.

Business Segment Deep Dive

Cardiovascular is the engine room. In Q1 2026, segment sales were $3.503B, up 13.5% reported and 11.2% operational/organic. Adjusted operating margin was 32.1%, down 170 bps Y/Y from 33.8%. Even with that margin pressure, the segment remains the company’s largest profit contributor and the source of most of its growth narrative.

Within Cardiovascular, Electrophysiology was the standout by scale and growth. Q1 revenue was $905M, up 23.9% reported and 21.7% organic. WATCHMAN delivered $506M, up 19.2% reported and 18.8% organic, though management said that result was below expectations because U.S. volumes softened as the quarter progressed. Interventional Cardiology and Vascular Therapies grew 7.8% organic, supported by Coronary Therapies, AGENT, imaging, TCAR, and Varithena. Interventional Oncology and Embolization added another growth leg with $268M in revenue and 15.2% organic growth.

MedSurg was slower but still positive. Q1 2026 sales were $1.701B, up 7.8% reported and 5.7% organic, with adjusted operating margin of 31.3%, down 200 bps Y/Y from 33.3%. Endoscopy generated $736M and grew 7% organic. Urology generated $646M but grew only 1% organic, reflecting weakness in stone management and sacral neuromodulation. Neuromodulation generated $318M and grew 15% organic, helped by Nalu and Intracept.

The segment picture is clear enough. BSX is not relying on one hero product. It has multiple growth vectors, but the current weight of evidence says Cardiovascular is carrying the load while parts of MedSurg need repair. That is not fatal. It just means the investment case depends on whether management can stabilize Urology and defend share in Electrophysiology while the stronger franchises continue to scale.

Flagship Product Analysis

The flagship products are WATCHMAN and the FARAPULSE electrophysiology ecosystem. WATCHMAN is Boston Scientific’s left atrial appendage closure device franchise. In Q1 2026, WATCHMAN produced $506M in revenue and 18.8% organic growth. That is still strong growth by any normal standard, but management explicitly called it below expectations because U.S. volumes weakened as the quarter progressed.

The more important fact is that clinical support for WATCHMAN continues to build. Management said CHAMPION data, presented in late March at ACC, achieved all primary and secondary endpoints and reinforced the safety and efficacy of WATCHMAN. Management also tied that evidence to possible guideline and label expansion efforts. In plain English, the current volume wobble is commercial and workflow-related, while the clinical case is still strengthening.

FARAPULSE is the other pillar. Electrophysiology revenue reached $905M in Q1 2026, up 21.7% organic, with 18% growth in the U.S. and 30% internationally according to management commentary. The ecosystem includes OPAL mapping, FARAVIEW, and FARAPOINT, and management highlighted strong catheter utilization plus continued international expansion. This is where Boston Scientific has been acting like the pace car in a fast race.

The issue is that the race got more crowded. Management said it is seeing increased competition from Medtronic, Johnson & Johnson, and Abbott, and reduced its 2026 Electrophysiology growth outlook to about 10% globally, with U.S. growth in the mid-single digits. That is a meaningful reset. Even so, a business growing around 10% after a period of hypergrowth is not a collapse. It is a normalization story, and the stock is trading more like a derailment story.

Innovation & Competitive Advantage

Boston Scientific’s moat is built from product breadth, physician relationships, clinical evidence, and a steady cadence of launches and acquisitions. The company serves 48M+ patients annually, has commercial representation in 127 countries, and invested about $2.0B in R&D according to the industry context supplied. In medtech, that combination matters because the sale is rarely just the device. It is the training, support, data, workflow fit, and trust built with physicians and hospital systems.

The innovation engine is visible in both recent launches and pipeline milestones. In Q1 2026, management highlighted PMDA approval in Japan for AGENT DCB, NMPA approval in China for OPAL HDx Mapping with FARAVIEW, FDA clearance for any day dosing enabled by the TheraSphere 360 platform, and ongoing expansion of FARAPOINT. It also pointed to future launches such as FARAWAVE Ultra in 1H 2027 and FANAFLEX in 2028.

Acquisitions are another part of the moat. BSX recently closed Valencia Technologies to complement Urology, had previously added Axonics and Silk Road Medical, and expects the announced Penumbra acquisition to close in the second half of 2026, subject to conditions cited by management. This is not empire building for its own sake. It is a deliberate strategy to keep the portfolio skewed toward faster-growth categories. The risk, of course, is integration. But the historical revenue trajectory, from $11.89B in 2021 to $20.07B in 2025, says management has used M&A as an accelerator rather than a distraction.

Operations & Supply Chain

Operations were good enough in Q1 2026 to support growth, but not clean enough to protect margins. Adjusted gross margin was 70.5%, down 100 bps Y/Y, and adjusted operating margin was 28.0% to 28.8% depending on the cited company material. Management tied the gross margin decline to tariffs and inventory charges related to the discontinuation of the POLARx Cryoablation system. It also said full-year 2026 adjusted gross margin is now expected to be slightly below 2025 because of lower-than-expected product mix benefit and incremental investments in global supply chain and quality systems.

There were also product-specific supply issues. Management said Endoscopy will continue to feel some AXIOS impact and other transient supply chain disruptions in Q2, though it expects improvement in 2H 2026. In Vascular Therapies, the company said it is ramping manufacturing supply for its Seismic peripheral IVL system over the course of the year. These are not broad signs of operational breakdown, but they do show that execution is carrying more friction than the market had become used to.

On the positive side, BSX still expects 50 to 75 bps of full-year 2026 adjusted operating margin expansion through OpEx leverage, spend controls, efficiency initiatives, and organizational optimization. That is a useful signal. It says management sees the current issues as mix and timing pressures rather than a structural cost problem. In medtech, supply chain trouble can act like sand in the gears. Here, the gears are still turning, just not as smoothly as in 2025.

Market Analysis

Boston Scientific is positioned in attractive medtech submarkets rather than in the broad health care equipment bucket. Management said the company competes in markets with weighted average market growth of about 8%, and the industry context highlights pulse field ablation, structural heart, therapeutic oncology, and certain minimally invasive categories as growth engines. That aligns well with BSX’s current portfolio mix.

The company’s own growth profile supports that positioning. Total revenue rose from $14.24B in 2023 to $16.75B in 2024 and $20.07B in 2025. Cardiovascular revenue rose from $8.819B in 2023 to $10.755B in 2024 and $13.266B in 2025. That is not just market growth. It reflects share gains, acquisitions, and category exposure. Q1 2026 still showed 9.4% organic growth despite a guidance cut, which suggests the end markets remain healthy even if some franchises are cooling from exceptional levels.

The most attractive market today is Electrophysiology, especially PFA. WATCHMAN also sits in a large addressable population. Management cited approximately 5M patients indicated for WATCHMAN today. In Forecast Context, the company was also described as having treated more than 500,000 FARAPULSE patients by year-end 2025 and more than 600,000 WATCHMAN patients by 2025. Those are large installed bases, but they also imply that these categories are moving from early adoption into broader standard-of-care battles, where competition intensifies and execution matters more.

Customer Profile

BSX sells primarily into hospitals, health systems, and physician specialists performing interventional procedures. The end customer is not the patient making a retail choice. It is the physician and hospital team deciding which device fits clinical evidence, workflow, reimbursement, and training support. That is why clinical data and salesforce execution matter so much here.

The customer mix differs by franchise. Electrophysiology products serve electrophysiologists and hospital EP labs. WATCHMAN depends on structural heart and electrophysiology workflows plus hospital scheduling and reimbursement. Endoscopy serves GI specialists. Urology and Pelvic Health depend on urologists and related outpatient or hospital settings. Neuromodulation relies on pain specialists and movement disorder physicians. This diversity helps reduce single-category risk, but it also means BSX must keep many clinical constituencies engaged at once.

Q1 2026 offered a useful reminder that the customer is buying workflow, not just hardware. WATCHMAN slowed because hospital capacity and reimbursement dynamics affected stand-alone cases. Urology underperformed partly because of commercial model disruption in sacral neuromodulation. Electrophysiology remained strong where catheter utilization and mapping footprint expanded. In other words, physician demand can be robust while revenue still slips if the commercial model or hospital throughput gets messy.

Competitive Landscape

Boston Scientific competes against Medtronic, Abbott, Johnson & Johnson MedTech, Edwards Lifesciences, Stryker, and a long tail of specialized device makers depending on the category. The competitive picture is most intense in Electrophysiology, structural heart, and interventional cardiology, where innovation cycles are fast and physician loyalty is earned one data set at a time.

Management was explicit that Electrophysiology is seeing more pressure. On the Q1 2026 call, Mike Mahoney said there are three other large players in the marketplace and named Medtronic, J&J, and Abbott. That matters because EP had been one of BSX’s cleanest growth stories. The company still expects to maintain leadership in PFA, but leadership in medtech is rarely a throne. It is more like a treadmill set a little too fast.

WATCHMAN also faces competitive and reimbursement-related pressure, though the supplied data emphasizes workflow and coverage dynamics more than a direct product threat. In Urology, China volume-based procurement and product gaps hurt stone management. In CRM, the business dealt with a physician advisory and tough comps. The broad takeaway is that BSX’s portfolio is strong, but not insulated. The company wins where it keeps clinical evidence fresh, launches on time, and supports physicians better than rivals.

Macro & Geopolitical Landscape

The macro backdrop for BSX is mixed but manageable. On the positive side, medical procedures are generally less cyclical than discretionary spending, and the company’s beta of 0.623 reflects that relative defensiveness. Aging populations, chronic disease burden, and continued adoption of minimally invasive procedures remain structural tailwinds for medtech demand.

The headwinds are more specific. Management cited tariffs as a factor behind Q1 gross margin pressure. It also cited a Middle East conflict impact on part of the high-voltage CRM business. In China, Urology and arterial businesses were affected by VBP, or volume-based procurement, which pressured growth. Foreign exchange helped Q1 2026 reported revenue by 220 bps, but management also said FX would create about a $0.04 headwind to full-year 2026 adjusted EPS.

These are real issues, but they are not thesis-breakers on their own. Tariffs and procurement pressure can squeeze margins and category growth. Geopolitical disruptions can weigh on certain product lines. Yet BSX’s geographic diversification helped offset some of that. In Q1 2026, the U.S. grew 11% operationally and Asia Pacific grew 12% operationally, while EMEA grew 1% operationally. That uneven pattern is exactly why global scale matters.

Balance Sheet Health

Income Statement Strength

Estimates Outlook

Valuation Assessment

Target Prices & Recommendation

Closing

Boston Scientific(BSX) is still one of the better large-cap medtech businesses in the market. The proof is in the numbers: revenue rose to $20.07B in 2025, Q1 2026 organic growth was 9.4%, Electrophysiology reached $905M in quarterly revenue, WATCHMAN generated $506M, free cash flow hit $3.66B in 2025, and the company has beaten EPS estimates in 7 straight reported quarters. Those are not the fingerprints of a franchise in decline.

What changed is confidence. Management cut 2026 guidance because Electrophysiology, WATCHMAN, and Urology all ran into friction at once. The market responded as markets often do, with the subtlety of a dropped anvil. But the operating data still points to a company with durable category positions, strong cash generation, and credible medium-term growth drivers.

That is why the fair value estimate of $74 matters. It recognizes that BSX deserves a discount to the old premium until management proves the reset is under control. It also recognizes that a stock at $50.34 is already discounting a harsher future than the facts currently justify. For medium-term investors who want quality growth without chasing perfection, BSX remains a Buy.